Previous close | 22.81 |
Open | 23.50 |
Bid | 21.30 x 100 |
Ask | 21.41 x 100 |
Day's range | 21.14 - 23.95 |
52-week range | 3.60 - 28.15 |
Volume | |
Avg. volume | 523,030 |
Market cap | 831.022M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.39 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.00 |
Insight into Longboard Pharmaceuticals' First Quarter Performance and Future Outlook
LA JOLLA, Calif., May 02, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
LA JOLLA, Calif., April 03, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN A